Device for maintaining vascularization near an implant

• US 7,332,330 B2
• Filed: 09/11/2001
• Issued: 02/19/2008
• Est. Priority Date: 09/11/2001
• Status: Expired due to Fees

• Current Assignee: Cytopherx, Inc., Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Renamed Biologics, Inc.
• Inventors: Tziampazis, Evangelos, Fissell, William H., Buffington, Deborah A., Humes, H. David
• Primary Examiner(s): Naff; David M.
• Application Number:
  US09/949,575
• Publication Number:
  US 20030050622A1
• Time in Patent Office: 2,352 Days
• Field of Search: 424/423, 435/177, 435/180, 435/395
• US Class Current: 435/297.1
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 31/005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 1/1678 intracorporal peritoneal dialysis A61M1/28
• CPC Class Codes: A61M 1/28 Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
• CPC Class Codes: B33Y 80/00 Products made by additive manufacturing

Abstract

A device and a method of maintaining vascularization near an implant, especially a bioartificial hemofilter. By associating cells that excrete angiogenic factors with such an implant, vascularization to the tissue surrounding the implant can be maintained. In a bioartificial hemofilter, this facilitates filtrate transport to a collection fiber for drainage from the body. The cells can be genetically engineered, for example using an adenovirus vector encoding for vascular endothelial growth factor. Myoblasts and myotubes may be used in one embodiment of the present invention.

Claims

1. An implantable hemofilter device capable of collecting an ultrafiltrate and comprising an ultrafiltrate collection network, and first cells,

wherein the first cells produce at least one angiogenic product,

wherein the ultrafiltrate collection network comprises a first permeable membrane component at least partially defining a first cavity and a second permeable membrane component at least partially defining a second cavity, and wherein the first and second cavities are exclusive of each other and are in fluid communication with each other,

wherein the first cavity contains the first cells,

wherein the second cavity collects the ultrafiltrate and remains essentially clear of the first cells, and wherein the angiogenic product of the first cells in the first cavity induces or maintains surrounding vascularization.

2. The device of claim 1, wherein the first cavity and the second cavity have a rectangular shape as defined by the first and second permeable membranes, respectively.

3. The device of claim 1, wherein the first cavity is in the form of a cylinder as defined by the first permeable membrane.

4. The device of claim 1, wherein the first cavity and the second cavity each have a helical geometry as defined by the first and second permeable membranes, respectively.

5. The device of claim 1, wherein at least one end of at least one of each of the first cavity and the second cavity are open.

6. The device of claim 1, wherein at least one end of at least one of each of the first cavity and the second cavity is capped.

7. The device of claim 1, wherein the first cavity has a spherical shape.

8. The device of claim 1, wherein the second cavity remains substantially clear of cells and cellular products other than said first cells and cellular products from said first cells.

9. The device of claim 1, wherein the first and the second cavities are contiguous and are partitioned from each other by a wall, to thereby form a double hollow fiber.

10. The device of claim 9, wherein the ultrafiltrate collection network comprises a plurality of double hollow fibers, and wherein the double hollow fibers are arranged substantially in parallel.

11. The device of claim 9, wherein the ultrafiltrate collection network comprises a plurality of the double hollow fibers and the double hollow fibers are connected to a manifold.

12. The device of claim 9, wherein the ultrafiltrate collection network comprises a plurality of the double hollow fibers, and the double hollow fibers are in fluid communication with each other.

13. The device of claim 9, wherein the ultrafiltration coefficient of the double hollow fiber is at least 20 mL/hr,Torr,m².

14. The device of claim 9, wherein the ultrafiltration coefficient of the double hollow fiber is at least 20 to 100 mL/hr,Torr,m².

15. The device of claim 9, wherein the double hollow fiber has a molecular weight cutoff of substantially equal to or less than 60,000 g/mole.

16. The device of claim 9, wherein the double hollow fiber is composed of a polymer.

17. The device of claim 9, wherein the double hollow fiber is composed of a material selected from the group consisting of polypropylenes, polysulfones, cellulosic polymers, rayons, polyacrylonitriles, polymethylmethacrylates, polycarbonates, polyfluoroethylenes and copolymers thereof.

18. The device of claim 1, which is in fluid communication with an implant body, wherein the implant body is composed of at least one material selected from the group consisting of glasses, metals, ceramics, and polymers.

19. The device of claim 18, wherein the implant body is composed of at least one polymer selected from the group consisting of a polypropylenes, polysulfones, cellulosic polymers, cellulose actetates, rayons, polyacrylonitriles, polymethylmethacrylates, polycarbonates, polyfluorethylenes, alginates, and chitosans.

20. The device of claim 1, wherein the angiogenic product is vascular endothelial growth factor.

21. The device of claim 1, wherein the first cells are transfected with a nucleic acid sequence which encodes the angiogenic product.

22. The device of claim 1, wherein the first cells are myoblasts.

23. The device of claim 22, wherein the myoblasts form a myotube.

24. The device of claim 18, wherein the first cells are supported on the implant body with an organic component.

25. The device of claim 24, wherein the organic component comprises fibrin glue.

26. The device of claim 1, wherein the hemofilter device contains in the second cavity additional cells which have a function other than producing an angiogenic product.

27. The device of claim 26, wherein the additional cells have a therapeutic function.

28. The device of claim 26, wherein the additional cells produce a therapeutically useful substance.

29. The device of claim 28, wherein the therapeutically useful substance is a hormone.

30. The device of claim 26, wherein the additional cells produce insulin.

31. The device of claim 26, wherein the additional cells are genetically modified.

32. The device of claim 26, wherein the additional cells have metabolic activity.

33. The device of claim 9, wherein the wall includes a permeable membrane material, whereby the first and second cavities are in fluid communication with each other through the wall.

34. The device of claim 9, wherein the wall includes an impermeable material, whereby the first and second cavities are in only indirect fluid communication with each other.

35. The device of claim 1, wherein the second cavity contains second cells, wherein the second cells are selected from the group consisting of stem cells, hematopoietic stem cells, hepatocytes, pancreatic islet cells and proximal tubule cells.